Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia

Warren H. Capell, Christopher A. DeSouza, Paul Poirier, Melanie L Bell, Brian L. Stauffer, Kathleen M. Weil, Teri L. Hernandez, Robert H. Eckel

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Objective - The objective of this study was to investigate the effects of lowering plasma triglycerides (TGs) on endothelial function and gain insight into the role played by free fatty acids (FFAs) in hypertriglyceridemia-associated vascular dysfunction. Methods and Results - Eleven hypertriglyceridemic subjects without coronary artery disease, diabetes, elevated low-density lipoprotein cholesterol, tobacco use, or hypertension were studied using a randomized, double-blinded, crossover design (fenofibrate and placebo, 14 days). After each regimen, forearm blood flow was assessed by plethysmography in response to arterial acetylcholine, nitroprusside, and verapamil infusion. Hourly plasma TGs, FFA, glucose, and insulin were measured during a 24-hour feeding cycle to characterize the metabolic environment. Changes in plasma FFA after intravenous heparin were used to estimate typical FFA accumulation in the luminal endothelial microenvironment. Fenofibrate lowered plasma TG (P<0.001), total cholesterol (P<0.01), and apolipoprotein B (P<0.01) without altering high-density lipoprotein or low-density lipoprotein cholesterol concentrations. Forearm blood flow in response to acetylcholine (P<0.0001), nitroprusside (P<0.001), and verapamil (P<0.0001) improved after fenofibrate. Fenofibrate lowered 24-hour (P<0.0001) and post-heparin (P<0.001) TG and tended to lower 24-hour (P=0.054) and post-heparin (P=0.028) FFA. Conclusions - Vascular smooth muscle function significantly improves after lowering plasma TG without changes in confounding lipoproteins or insulin resistance. The data raise additional questions regarding the role of FFA in hypertriglyceridemia-associated vascular dysfunction.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume23
Issue number2
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Fenofibrate
Hypertriglyceridemia
Vasodilator Agents
Nonesterified Fatty Acids
Triglycerides
Nitroprusside
Heparin
Verapamil
Forearm
LDL Cholesterol
Acetylcholine
Blood Vessels
Cholesterol
Plethysmography
Apolipoproteins B
Tobacco Use
HDL Lipoproteins
Vascular Smooth Muscle
Cross-Over Studies
Lipoproteins

Keywords

  • Endothelial function
  • Free fatty acids
  • Lipoprotein lipase
  • Metabolic syndrome
  • Postprandial lipemia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. / Capell, Warren H.; DeSouza, Christopher A.; Poirier, Paul; Bell, Melanie L; Stauffer, Brian L.; Weil, Kathleen M.; Hernandez, Teri L.; Eckel, Robert H.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 23, No. 2, 01.02.2003, p. 307-313.

Research output: Contribution to journalArticle

Capell, Warren H. ; DeSouza, Christopher A. ; Poirier, Paul ; Bell, Melanie L ; Stauffer, Brian L. ; Weil, Kathleen M. ; Hernandez, Teri L. ; Eckel, Robert H. / Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2003 ; Vol. 23, No. 2. pp. 307-313.
@article{864d1fc9d6d54625987b595dd23b33f1,
title = "Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia",
abstract = "Objective - The objective of this study was to investigate the effects of lowering plasma triglycerides (TGs) on endothelial function and gain insight into the role played by free fatty acids (FFAs) in hypertriglyceridemia-associated vascular dysfunction. Methods and Results - Eleven hypertriglyceridemic subjects without coronary artery disease, diabetes, elevated low-density lipoprotein cholesterol, tobacco use, or hypertension were studied using a randomized, double-blinded, crossover design (fenofibrate and placebo, 14 days). After each regimen, forearm blood flow was assessed by plethysmography in response to arterial acetylcholine, nitroprusside, and verapamil infusion. Hourly plasma TGs, FFA, glucose, and insulin were measured during a 24-hour feeding cycle to characterize the metabolic environment. Changes in plasma FFA after intravenous heparin were used to estimate typical FFA accumulation in the luminal endothelial microenvironment. Fenofibrate lowered plasma TG (P<0.001), total cholesterol (P<0.01), and apolipoprotein B (P<0.01) without altering high-density lipoprotein or low-density lipoprotein cholesterol concentrations. Forearm blood flow in response to acetylcholine (P<0.0001), nitroprusside (P<0.001), and verapamil (P<0.0001) improved after fenofibrate. Fenofibrate lowered 24-hour (P<0.0001) and post-heparin (P<0.001) TG and tended to lower 24-hour (P=0.054) and post-heparin (P=0.028) FFA. Conclusions - Vascular smooth muscle function significantly improves after lowering plasma TG without changes in confounding lipoproteins or insulin resistance. The data raise additional questions regarding the role of FFA in hypertriglyceridemia-associated vascular dysfunction.",
keywords = "Endothelial function, Free fatty acids, Lipoprotein lipase, Metabolic syndrome, Postprandial lipemia",
author = "Capell, {Warren H.} and DeSouza, {Christopher A.} and Paul Poirier and Bell, {Melanie L} and Stauffer, {Brian L.} and Weil, {Kathleen M.} and Hernandez, {Teri L.} and Eckel, {Robert H.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1161/01.ATV.0000046230.02211.B4",
language = "English (US)",
volume = "23",
pages = "307--313",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia

AU - Capell, Warren H.

AU - DeSouza, Christopher A.

AU - Poirier, Paul

AU - Bell, Melanie L

AU - Stauffer, Brian L.

AU - Weil, Kathleen M.

AU - Hernandez, Teri L.

AU - Eckel, Robert H.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Objective - The objective of this study was to investigate the effects of lowering plasma triglycerides (TGs) on endothelial function and gain insight into the role played by free fatty acids (FFAs) in hypertriglyceridemia-associated vascular dysfunction. Methods and Results - Eleven hypertriglyceridemic subjects without coronary artery disease, diabetes, elevated low-density lipoprotein cholesterol, tobacco use, or hypertension were studied using a randomized, double-blinded, crossover design (fenofibrate and placebo, 14 days). After each regimen, forearm blood flow was assessed by plethysmography in response to arterial acetylcholine, nitroprusside, and verapamil infusion. Hourly plasma TGs, FFA, glucose, and insulin were measured during a 24-hour feeding cycle to characterize the metabolic environment. Changes in plasma FFA after intravenous heparin were used to estimate typical FFA accumulation in the luminal endothelial microenvironment. Fenofibrate lowered plasma TG (P<0.001), total cholesterol (P<0.01), and apolipoprotein B (P<0.01) without altering high-density lipoprotein or low-density lipoprotein cholesterol concentrations. Forearm blood flow in response to acetylcholine (P<0.0001), nitroprusside (P<0.001), and verapamil (P<0.0001) improved after fenofibrate. Fenofibrate lowered 24-hour (P<0.0001) and post-heparin (P<0.001) TG and tended to lower 24-hour (P=0.054) and post-heparin (P=0.028) FFA. Conclusions - Vascular smooth muscle function significantly improves after lowering plasma TG without changes in confounding lipoproteins or insulin resistance. The data raise additional questions regarding the role of FFA in hypertriglyceridemia-associated vascular dysfunction.

AB - Objective - The objective of this study was to investigate the effects of lowering plasma triglycerides (TGs) on endothelial function and gain insight into the role played by free fatty acids (FFAs) in hypertriglyceridemia-associated vascular dysfunction. Methods and Results - Eleven hypertriglyceridemic subjects without coronary artery disease, diabetes, elevated low-density lipoprotein cholesterol, tobacco use, or hypertension were studied using a randomized, double-blinded, crossover design (fenofibrate and placebo, 14 days). After each regimen, forearm blood flow was assessed by plethysmography in response to arterial acetylcholine, nitroprusside, and verapamil infusion. Hourly plasma TGs, FFA, glucose, and insulin were measured during a 24-hour feeding cycle to characterize the metabolic environment. Changes in plasma FFA after intravenous heparin were used to estimate typical FFA accumulation in the luminal endothelial microenvironment. Fenofibrate lowered plasma TG (P<0.001), total cholesterol (P<0.01), and apolipoprotein B (P<0.01) without altering high-density lipoprotein or low-density lipoprotein cholesterol concentrations. Forearm blood flow in response to acetylcholine (P<0.0001), nitroprusside (P<0.001), and verapamil (P<0.0001) improved after fenofibrate. Fenofibrate lowered 24-hour (P<0.0001) and post-heparin (P<0.001) TG and tended to lower 24-hour (P=0.054) and post-heparin (P=0.028) FFA. Conclusions - Vascular smooth muscle function significantly improves after lowering plasma TG without changes in confounding lipoproteins or insulin resistance. The data raise additional questions regarding the role of FFA in hypertriglyceridemia-associated vascular dysfunction.

KW - Endothelial function

KW - Free fatty acids

KW - Lipoprotein lipase

KW - Metabolic syndrome

KW - Postprandial lipemia

UR - http://www.scopus.com/inward/record.url?scp=0037324362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037324362&partnerID=8YFLogxK

U2 - 10.1161/01.ATV.0000046230.02211.B4

DO - 10.1161/01.ATV.0000046230.02211.B4

M3 - Article

VL - 23

SP - 307

EP - 313

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 2

ER -